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The crystal structure of lumazine synthase from Bacillus
anthracis was solved by molecular replacement and reﬁned to
Rcryst = 23.7% (Rfree = 28.4%) at a resolution of 3.5 A ˚ .T h e
structure reveals the icosahedral symmetry of the enzyme and
speciﬁc features of the active site that are unique in
comparison with previously determined orthologues. The
application of isothermal titration calorimetry in combination
with enzyme kinetics showed that three designed pyrimidine
derivatives bind to lumazine synthase with micromolar
dissociation constants and competitively inhibit the catalytic
reaction. Structure-based modelling suggested the binding
modes of the inhibitors in the active site and allowed an
estimation of the possible contacts formed upon binding. The
results provide a structural framework for the design of
antibiotics active against B. anthracis.
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1. Introduction
Riboﬂavin (compound 4, Fig. 1) is essential in all organisms as
a precursor for ﬂavocoenzymes. With the exception of Listeria
monocytogenes, pathogenic bacteria biosynthesize riboﬂavin
de novo, whereas animals depend on nutritional sources. In
certain bacterial pathogens (Salmonella, Brucella), enzymes
of the riboﬂavin-biosynthesis pathway have documented
virulence-factor status. Owing to the absence of the riboﬂavin-
biosynthesis pathway in animals, the enzymes of the pathway
are potential targets for anti-infective therapy and riboﬂavin-
biosynthesis inhibitors should be exempt from target-related
toxicity.
The biosynthesis of riboﬂavin has been studied in consid-
erable detail and it is known that the early steps show
signiﬁcant differences between taxonomic kingdoms, although
the ﬁnal two steps, namely the formation of 6,7-dimethyl-
8-ribityllumazine (compound 3, Fig. 1) and riboﬂavin
(compound 4), are both strictly conserved in all organisms. Six
enzymes are known to date to be involved in the riboﬂavin-
biosynthetic pathway in eubacteria: GTP cyclohydrolase II,
2,5-diamino-6-ribosylamino-4(3H)-pyrimidinone 50-phosphate
deaminase, 5-amino-6-ribosylamino-2,4(1H,3H)-pyrimidine-
dione 50-phosphate reductase, 3,4-dihydroxy-2-butanone 4-
phosphate synthase, 6,7-dimethyl-8-ribityllumazine synthase
(LS) and riboﬂavin synthase. LS and riboﬂavin synthase
catalyze the terminal reactions in the process. More speciﬁ-
cally, LS catalyzes the condensation of 5-amino-6-ribityl-
amino-2,4(1H,3H)-pyrimidinedione (compound 1, Fig. 1) with
3,4-dihydroxybutanone 4-phosphate (compound 2), affording
6,7-dimethyl-8-ribityllumazine (compound 3), and riboﬂavin
synthase catalyzes the dismutation of two molecules ofcompound 3 to form one molecule each of riboﬂavin
(compound 4) and compound 1.
Structural, biochemical and genetic studies of LS have a
long and successful history. Structures of LS from different
organisms have been solved at near-atomic resolution (Ritsert
et al., 1995; Persson et al., 1999; Meining et al., 2000; Braden et
al., 2000; Liao et al., 2001; Zhang et al., 2001; Gerhardt et al.,
2002; Morgunova et al., 2005, 2007). The enzymes show 30–
48% sequence identity (Fig. 2) and occur in three oligomer-
ization states. LS from Saccharomyces cerevisiae, Schizo-
saccharomyces pombe, Magnaporthe grisea, Mycobacterium
tuberculosis and Candida albicans assembles into homo-
pentamers (Persson et al., 1999; Meining et al., 2000; Gerhardt
et al., 2002; Morgunova et al., 2005, 2007). LS from Brucella
abortus has been shown to form D5-symmetric dimers of
pentamers (Klinke et al., 2005). The enzymes from Bacillus
subtilis, Aquifex aeolicus, Escherichia coli and Spinacia oler-
acea form icosahedral capsids constituted of 60 identical
subunits, which can be described as dodecamers of pentamers.
Moreover, B. subtilis also forms a 1 MDa enzyme complex
consisting of an LS capsid with three riboﬂavin synthase
subunits enclosed in the central core (Ladenstein et al., 1988;
Ritsert et al., 1995). The topology of the homopentameric
enzymes resembles that of the pentameric building blocks of
the icosahedral and decameric enzymes.
Catalysis occurs in equivalent active sites, which are located
at the interfaces of adjacent subunits in the pentamers. Based
on the structures of the substrates and product of the reaction
catalyzed by LS, numerous organic compounds have been
synthesized and characterized kinetically as well as thermo-
dynamically as inhibitors of LS from M. tuberculosis,
Brucella abortus and C. albicans (Cushman et al., 1997, 2001,
2002, 2004, 2005; Cushman, Mavandadi et al., 1999; Cushman,
Mihalic et al., 1999a,b; Braden et al., 2000; Chen et al., 2005;
Zhang et al., 2008).
Whereas several biosynthetic path-
ways of Bacillus anthracis have been
investigated in some detail, very little is
known about riboﬂavin biosynthesis in
this bacterium. In order to suggest
possible lead compounds for potential
drugs against this pathogen, we deter-
mined the three-dimensional structure
of B. anthracis lumazine synthase
(BaLS) and performed kinetic assays,
isothermal titration calorimetry binding
studies and structure-based modelling
for several synthetic ligands.
2. Material and methods
2.1. Cloning and bacterial cell culture
In order to construct an open reading
frame for the expression of BaLS, we
cloned theorthologous geneofB.cereus
while replacing the codon for the single
amino-acid residue that differs between
the two orthologues. Speciﬁcally, we
ampliﬁed the B. cereus gene using the
oligonucleotides BARibH-Rbs-EcoRI
and BARibH-BamHI-Hi (designed to
introduce the desired Q151H replace-
ment) as PCR primers (see Table 1).
The ampliﬁcate was puriﬁed and
digested with EcoRI and BamHI. The
fragment was cloned into the pNCO-113
plasmid which had been treated with
the same enzymes. The recombinant
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Figure 1
Terminal steps of riboﬂavin biosynthesis. 1, 5-Amino-6-ribitylamino-2,4(1H,3H)-pyrimidinedione;
2, 3,4-dihydroxy-2-butanone-4-phosphate; 3, 6,7-dimethyl-8-ribityl-lumazine; 4, riboﬂavin.
Table 1
The oligonucleotides used for the cloning of lumazine synthase from
B. anthracis.
Primer
Novel restriction
site Sequence (50!30)
BARibH-Rbs-EcoRI EcoRI ATA ATA GAA TTC ATT AAA
GAG GAG AAA TTA ACT
BARibH-BamHI-Hi BamHI TAT TAT GGA TCC TTA TGC
CCA ATG TTT TGA TAAplasmid carrying the BaLS gene was transformed into XL1 E.
coli cells. The plasmid was re-isolated and transformed into E.
coli M15 [pREP4] cells (Stu ¨ber et al., 1990) carrying the
pREP4 repressor plasmid for the overexpression of lac
repressor protein, where it directed the synthesis of full-length
BaLS (without tags or any other additions). Kanamycin
(15 mg l
 1) and ampicillin (170 mg l
 1) were added to secure
the retention of both plasmids in the host strain. The cultures
were incubated at 310 K with shaking. At an optical density of
0.7 (at 600 nm), isopropyl  -d-1-thiogalactopyranoside was
added to a ﬁnal concentration of 2 mM and the cultures were
incubated for 5 h at 310 K with shaking. The cells were
harvested by centrifugation, washed with 0.9%(w/v) sodium
chloride and stored at 253 K.
2.2. Purification
All puriﬁcation steps were performed at 277 K. Frozen cell
mass ( 5 g) was thawed in 30 ml 50 mM potassium phosphate
pH 8.0 containing 10 mM EDTA. The suspension was ultra-
sonically treated and centrifuged. The supernatant was passed
through a column of Q Sepharose (5   10 cm; Amersham
Pharmacia Biotech, Freiburg, Germany) which had been
equilibrated with 20 mM potassium phosphate pH 8.0 (buffer
A). The column was washed with 100 ml buffer A and devel-
oped with a linear gradient of 20–1000 mM potassium phos-
phate pH 8.0 in a total volume of 900 ml. The fractions were
combined, concentrated by ultraﬁltration and dialyzed against
100 mM potassium phosphate pH 8.0 (buffer B). The solution
was passed through a column of Superdex 200 (2.6   60 cm;
Amersham Pharmacia Biotech, Freiburg, Germany) which
had been equilibrated with buffer B. The protein was eluted
with buffer B and concentrated by ultraﬁltration.
2.3. Protein sequencing
Sequence determination was performed by the automated
Edman method using a 471A Protein Sequencer (Perkin–
Elmer).
2.4. Inhibitors
4-(6-Chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-yl)-n-
butyl 1-phosphate (JC33), 5-(6-chloro-2,4-dioxo-1,2,3,4-tetra-
hydropyrimidine-5-yl)-n-pentyl 1-phosphonate (JC72) and
5-(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-yl)-6-keto-
n-hexyl 1-phosphate (TS23) were prepared as described
elsewhere (Cushman, Mihalic et al., 1999b; Cushman et al.,
2004, 2005).
2.5. Crystallization and data collection
BaLS crystals were grown by the vapour-diffusion tech-
nique in sitting drops by the following procedure: 1 ml protein
solution (17 mg ml
 1) in 100 mM potassium phosphate pH 8.0
was mixed with 1 ml reservoir solution (100 mM Tris–HCl pH
8.0, 36% polypropylene glycol P400 and 20 mM DTT). Thin
fragile plate-shaped crystals appeared in one month and grew
to dimensions of 0.05   0.1  
0.4 mm in several weeks.
X-ray diffraction data were
collected from a single crystal on
beamline ID23-1 at the European
Synchrotron Light Source (ESRF,
Grenoble, France) at 100 K using
the reservoir solution as a cryo-
protectant. The data-collection
strategy was optimized with the
program BEST (Bourenkov &
Popov, 2006). The data were
integrated with the program XDS
(Kabsch, 1988, 2010) and scaled
with SCALA (Collaborative
Computational Project, Number
4, 1994). The crystals belonged to
the orthorhombic system, space
group P21212, with unit-cell para-
meters a = 157.2, b = 222.3,
c = 473.5 A ˚ . Statistics of data
collection are presented in
Table 2.
2.6. Structure determination
The structure of BaLS was
solved by molecular replacement
using the programs MOLREP
and FFFEAR as implemented in
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Figure 2
Amino-acid sequence alignment of the icosahedral lumazine synthases from B. anthracis, B. subtilis,
A. aeolicus and S. oleracea with two pentameric lumazine synthases from M. tuberculosis and C. albicans.
The numbering corresponds to the enzyme from B. anthracis. The secondary-structure elements are shown
below the sequences as they are found in BaLS. The residues highlighted in yellow and cyan are involved in
the formation of the active site and the binding of inhibitors, respectively. The part of the structure which is
responsible for the formation of the icosahedral assembly is highlighted in magenta.CCP4 (Collaborative Computational Project,Number 4, 1994)
with the structure of a half icosahedron of B. subtilis LS (PDB
code 1rvv; Ritsert et al., 1995) as a Patterson search model.
2.7. Refinement
The initial model consisting of three halves of the icosa-
hedral particle, each of which contained six pentamers, was
subjected to rigid-body reﬁnement with PHENIX (Adams
et al., 2002) and REFMAC (Collaborative Computational
Project, Number 4, 1994). A special version of REFMAC was
used which could handle 150 000 non-H atoms. Solvent ﬂat-
tening and histogram matching were applied to the initial
electron density with the program DM as implemented in
CCP4 (Collaborative Computational Project, Number 4,
1994). Noncrystallographic averaging was performed between
the 18 pentamers belonging to the three half icosahedra using
the program DM. The mask covering one pentamer was
calculated with NCS-MASK (Collaborative Computational
Project, Number 4, 1994) and the noncrystallographic sym-
metry operators were improved after every cycle of averaging.
The procedure improved the initial electron-density map and
allowed the building of almost all of the residues that had been
replaced by alanine in the original model. The model was
rebuilt with the graphics programs O (Jones et al., 1991) and
Coot (Emsley & Cowtan, 2004). Further reﬁnement was
performed with REFMAC and phenix.reﬁne using TLS
options and noncrystallographic restraints between pentamers
inside the icosahedral particle and between subunits in one
pentamer. The progress of reﬁnement was monitored by the
free R factor using 2% (4118 reﬂections) of the data put aside
from the calculations. The difference |Fo|   |Fc| electron-
density maps showed positive 5  peaks in each active site near
the positions of phosphate ions or phosphate-group binding
sites in the other known LS structures. Since the protein was
isolated and stored in 100 mM potassium phosphate buffer,we
interpreted these peaks as phosphate ions. The ﬁnal model
consisting of 90 protein subunits and 90 phosphate ions was
reﬁned at a resolution of 3.5 A ˚ to Rcryst = 23.7% and
Rfree = 28.4%. The atomic coordinates and structure factors of
BaLS have been deposited in the Protein Data Bank (three
ﬁles with accession codes 1vsx, 1vsw and 3jv8).
2.8. Isothermal titration calorimetry (ITC)
Calorimetric measurements were carried out on a VP Iso-
thermal Titration Calorimeter (MicroCal Inc., Northampton,
Massachusetts, USA) calibrated with standard electrical
pulses. Solutions containing 0.03 mM BaLS (on the basis of
monomers) and 50 mM potassium phosphate pH 7.0 were
titrated with 5 mM inhibitor in the same buffer. All solutions
were degassed by stirring under vacuum before use. Titrations
were performed at 303 K with injected aliquots of 4 ml inhi-
bitor solution. A total of 25–30 injections were made, with
240 s between injections. In control experiments the inhibitor
was titrated against the buffer solution without protein in
order to determine the dilution heat of the inhibitor. The
background was subsequently subtracted from the test data
involving BaLS. All data were evaluated using the Origin 5.0
software package (MicroCal). The apparent association
constant Ka =1 / Kd, binding enthalpy H and stoichiometry n,
together with their corresponding standard deviations, were
determined by a nonlinear least-squares ﬁt. The entropy and
free energy of binding were obtained from the relation
G =  RTlnKa = H   TS.
2.9. Kinetic assay of BaLS inhibitors
Assay mixtures contained 100 mM Tris–HCl pH 7.0,
100 mM NaCl, 5 mM dithiothreitol, 1%(v/v) DMSO, 100 mM
compound 2 (Fig. 1), 1 mM BaLS (on the basis of monomers)
and variable concentrations of compound 1 (3–80 mM; Fig. 1)
and inhibitor (0–45 mM) in a volume of 0.2 ml. Assay mixtures
were prepared as follows. A solution (170 ml) containing
105 mM Tris–HCl pH 7.0, 105 mM NaCl, 5.3 mM dithio-
threitol, 118 mM compound 2 and 1.18 mM BaLS (on the basis
of monomers) was added to 10 ml DMSO containing 0–
10 nmol inhibitor in a well of a 96-well microtitre plate. The
reaction was started by adding 20 ml of a solution containing
105 mM Tris–HCl pH 7.0, 105 mM NaCl, 5.3 mM dithio-
threitol and compound 1 (30–800 mM). Formation of
compound 3 was monitored photometrically at 408 nm and
300 K with a computer-controlled plate reader ("compound 3 =
10 200 M
 1 cm
 1). Samples were measured at intervals of 20 s
for a total period of 30 min.
2.10. Evaluation of kinetic data
The velocity/substrate-concentration data were ﬁtted for all
inhibitor concentrations with a nonlinear regression method
using the program DynaFit (Kuzmic, 1996). Different inhibi-
tion models were considered for the calculation. Ki and Kis
research papers
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Table 2
Data-collection and reﬁnement statistics.
Values in parentheses are for the outer shell.
Data collection
Resolution limits (A ˚ ) 40–3.5 (3.69–3.5)
No. of observed reﬂections 1028468 (150011)
No. of unique reﬂections 196243 (28170)
Completeness (%) 93.3 (93.5)
Multiplicity 5.3 (5.3)
hI/ (I)i 5.2 (2.2)
Rp.i.m.† (%) 12.9 (37.4)
Reﬁnement
Resolution range (A ˚ ) 15–3.5
Non-H protein atoms 101742
Non-H ion atoms 450
Rcryst overall‡ (%) 23.7
Rfree§ (%) 28.4
Ramachandran plot
Most favourable regions (%) 85.3
Allowed regions (%) 14.7
Generously allowed regions (%) 0.0
R.m.s. standard deviation
Bond lengths (A ˚ ) 0.002
Bond angles ( ) 0.54
† Rp.i.m. is the precision-indicating (multiplicity-weighted) Rmerge (Diederichs & Karplus,
1997). ‡ Rcryst =
P
hkl
   jFobsj j Fcalcj
   =
P
hkl jFobsj.§ Rfree is the cross-validation R
factor computed for a test set of 5% of the unique reﬂections.values   standard deviations were obtained from the ﬁt
considering the most likely inhibition model.
2.11. Molecular modelling
The respective inhibitors were initially pre-docked into the
active site of BaLS by the following procedure. The empty
BaLS active site was structurally aligned with the structure of
the active site of LS from M. tuberculosis (MtLS) in complex
with JC33. Compounds JC72 and TS23 were ﬁrst overlaid with
JC33 in the active site of MtLS. The hypothetical complexes
were structurally aligned with the empty BaLS dimer. The
structural alignment was performed with the least-squares
option (lsq) as implemented in O. The ﬁnal docking of the
inhibitor models to the binding site of BaLS was performed
with AutoDock 3.0 (Morris et al., 1998). The protein model
was protonated and partial charges were added using Chimera
(Pettersen et al., 2004) and the solvation parameters were
deﬁned using the AutoDock 3.0 routine Mol2topdbqs (Wang
et al., 2006) after removal of the ions found in the structure.
The respective inhibitor models were prepared for the docking
procedure using Chimera (Pettersen et al., 2004). The docking
was performed on a rigid dimer of BaLS subunits that were
directly adjacent in a pentamer module, while the ligand was
allowed to adopt different conformations. The docking grid
was centred on the centre of gravity of the putative binding
site. All other parameters remained at their default values.
20 dockings for each inhibitor were calculated using the
Lamarckian genetic algorithm (Morris et al., 1998). In order to
test the changes that occur in the conformations of protein
side chains upon inhibitor binding, the most reliable models
were subjected to 1000 steps of molecular-dynamics calcula-
tions followed by 300 steps of energy minimization. Molecular-
dynamics calculations were performed with the program CNS
(Bru ¨nger et al., 1998) by using a simulated-annealing schedule
in Cartesian coordinates at a constant temperature of 298 K, a
dielectric constant of 1.0 for the protein and the nonbonded
list cutoff of 13 A ˚ as default values in CNS. The pictures in
Figs. 3 and 7 were generated by PyMOL (DeLano, 2002).
3. Results and discussion
3.1. Protein purification
Full-length BaLS (without tags or other additions) was
isolated from a recombinant E. coli strain as described in x2.
The recombinant protein was puriﬁed by ion-exchange and
gel-permeation chromatography and appeared to be homo-
geneous as judged by SDS–PAGE. The N-terminal sequence
of the recombinant protein was veriﬁed by partial Edman
degradation, affording the sequence motif MVFEGHLVGT,
which was in perfect agreement with the translated open
reading frame.
3.2. Overall protein structure and comparison with
orthologous structures
BaLS was crystallized as described in x2. The three-
dimensional structure was solved by molecular replacement
using one half-molecule of the icosahedral B. subtilis LS (PDB
code 1rvv; Ritsert et al., 1995) as a Patterson search model.
The asymmetric unit of the BaLS crystal contained 90 protein
subunits of 16 255 Da molecular mass with a Matthews co-
efﬁcient of 2.83 A ˚ 3 Da
 1 (i.e. three icosahedral half-molecules;
see Fig. 3a). Each BaLS molecule consists of 60 identical
protein subunits arranged in 12 pentamers in accordance with
icosahedral 532 symmetry (Figs. 3b and 3c). The BaLS
monomer is comprised of 153 amino acids and shows the
typical  / / -sandwich topology of known LS orthologues.
The core of the protein subunit is formed by a four-stranded
parallel  -sheet which is ﬂanked by  -helices (Fig. 3c).
Sequence (Fig. 2) and structural comparisons of the BaLS
subunit with icosahedral orthologues showed a very high
similarity for secondary-structure elements and only small
differences in the conformations of the loops connecting
 -strands and  -helices (Fig. 3d). On the other hand,
comparison of the BaLS subunit with pentameric (non-
icosahedral) LSs (Fig. 3e) revealed more distinct differences in
the loop regions, although the secondary-structure elements
appeared to be rather conserved between icosahedral and
pentameric enzymes.
The symmetry-related  3 helices of each pentameric
ensemble of icosahedral BaLS surround a central channel.
The central part of the channel wall is formed by the side
chains of ﬁve Lys97 residues, creating a positively charged
patch whose charge is compensated by the side chains of
Glu94. The channel entrances are formed by the polar resi-
dues Asp89 and Asn93 and by Gln105 and Glu118, which face
the solvent space and the particle core space, respectively. The
amino-acid side chains inside the channel participate in
stabilizing hydrogen-bond interactions. While the solvent
content of the BaLS crystals could not be analyzed in detail,
water molecules have been observed inside the homologous
channels of other LS orthologues.
The N-terminus of each subunit forms an extra  -strand
extending to the  -sheet of the adjacent subunit. 12 penta-
meric blocks make up one icosahedral particle with a diameter
of about 157 A ˚ , which is rather similar to the previously
determined sizes of icosahedral LSs [160 A ˚ for LS from
S. oleracea (Persson et al., 1999), 154 A ˚ for LS from A. aeolicus
(Zhang et al., 2001) and 156 A ˚ for LS from B. subtilis (Ritsert
et al., 1995)]. The characteristic icosahedral ionic contacts
described in detail by Zhang et al. (2001) are well conserved
in the BaLS structure, although there is one fewer positively
charged Arg residue compared with LS from the hyperther-
mophilic bacterium A. aeolicus. The residues involved in the
ionic interactions are Arg20, Arg39, Glu23, Asp35 and
Glu144. The threefold interactions are formed by residues
from helices  1 and  4. This contact is also well conserved in
all known icosahedral LSs and is maintained by the hydrogen-
bond network of three symmetry-equivalent Lys28 residues
from neighbouring subunits on the surface of the capsid, by
hydrophobic interactions involving Phe24, Ile120 and Ile124
and by three negatively charged Glu121 residues on the inner
surface of the capsid. The twofold icosahedral axes at the
interface between two pentamers are surrounded by residues
research papers
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Figure 3
Structural diagrams of lumazine synthase from BaLS. (a) Packing of three icosahedral halves in the asymmetric unit of the P21212 crystal lattice. (b)
Icosahedral assembly of the enzyme. The view is along the ﬁvefold icosahedral axis. Each pentamer is shown in a different colour and inorganic
phosphate ions found in the active sites are shown as spheres. (c) Labelled secondary-structure arrangement of a monomer. (d) Structural comparison of
BaLS with icosahedral LSs from B. subtilis, A. aeolicus and Spinacia oleacea; BaLS is shown in red. (e) Structural comparison of BaLS with pentameric
enzymes from M. tuberculosis, Schizosaccharomyces pombe, Saccharomyces cerevisiae and Brucella abortus; BaLS is shown in red. (f) Stereodiagram of
the 2|Fo|   |Fc| electron-density map around the active site of the enzyme with bound inorganic phosphate ion; the residues of a symmetry-equivalent
adjacent subunit are labelled with primes.from the end of strand  4 and the loop connecting helices  4
and  5. The interactions between pairs of adjacent subunits
inside the pentamer are very extensive.
3.3. Active site
The cavities formed at the subunit interfaces are the active
sites of lumazine synthase where both substrates (i.e. com-
pounds 1 and 2; Fig. 1) are bound. Notably, all icosahedral LSs
including BaLS have 60 equivalent active sites. The hetero-
aromatic ring systems of compound 1 or substrate-analogous
inhibitors are located in a hydrophobic pocket. Their ribityl
side chain is embedded in a surface depression which is less
accessible to solvent than the ring system and the alkylphos-
phonyl or alkylphosphate chain. The binding of substrate-
analogous inhibitors to LS appears to follow an induced-ﬁt
mechanism as follows. The phenyl ring of Phe20 swings into an
orientation parallel to the heteroaromatic ring system of the
inhibitors ( –  interaction), whereas in the native enzyme
forms it is usually tilted away by more than 30  relative to this
orientation. Position 20 is occupied by either a Phe or a Trp
residue in orthologous LSs. This residue acts like a ‘gate’
controlling the path between the active-site cavity and the
solvent environment. Arg125, which is involved in forming
an ionic contact with the phosphonate or phosphate group of
the inhibitors, is highly conserved throughout the compared
orthologous LSs, like all other amino-acid side chains lining
the wall of the active-site cavity. Arg125 forms a salt bridge
with Glu131.
The structures of several complexes of LSs with substrate
and product analogues (Ritsert et al., 1995; Persson et al., 1999;
Meining et al., 2000; Gerhardt et al., 2002; Zhang et al., 2003,
2008; Klinke et al., 2005; Morgunova et al., 2005, 2006, 2007)
together with mutation analysis performed for B. subtilis LS
showed that residues Phe21, Phe59, Thr79, Ile81, Thr85 and
His87 from one subunit, and residues Arg126, Lys134 and
Glu137 (BaLS numbering) from the adjacent subunit
surprisingly have only a weak inﬂuence on substrate binding
and catalysis (Kis & Bacher, 1995; Kis et al., 1995), pointing to
the control of activation entropy (Fischer et al., 2003) and the
proximity effect as the main driving forces in LS catalysis. In
the absence of substrates or products a phosphate ion usually
remains bound at the putative location of the substrate
(compound 2, Fig. 1; Persson et al., 1999; Braden et al., 2000;
Zhang et al., 2001; Morgunova et al., 2007). BaLS was crys-
tallized from phosphate buffer. In the resulting structure, we
found electron-density peaks at the 5  level in each of the
90 active sites in the asymmetric unit. These densities were
interpreted and reﬁned as inorganic phosphate ions. The
binding mode of the phosphate ion found in the BaLS struc-
ture is very similar to the phosphate-binding modes described
in published LS structures. Each phosphate ion establishes
electrostatic contacts with side-chain N atoms of Arg126 and
hydrogen bonds with main-chain O and N and side-chain O
atoms of Thr85, as well as with the main-chain N atom of
Ala84 (Fig. 3f). Both Arg126 and Thr85
are strictly conserved among all known
LSs. It has been shown previously that
mutation of the Arg126 residue to
histidine or lysine reduced the enzy-
matic activity to 62% and 9%, respec-
tively, while mutation to an uncharged
residue resulted in inactive enzyme
(Fischer et al., 2003). In icosahedral LSs
any two active sites are connected by
twofold icosahedral axes and the
distance between two C2 symmetry-
related phosphate ions is 15.4 A ˚ . These
twofold-symmetric regions of the
icosahedral assembly form pore-like
structures which could serve as alter-
native exit paths for the product of the
catalytic reaction (Ladenstein et al.,
2009).
3.4. Bisubstrate-type LS inhibitors
The complex reaction mechanism of
LS has been studied in considerable
detail. A crucial step is the initial
formation of a covalent bond between
the two substrate molecules, compounds
1 and 2 (Fig. 1), which results in the
formation of the Schiff-base-type inter-
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Figure 4
Top, reaction mechanism of lumazine synthase. Bottom, the inhibitors used in this study.mediate compound 5 (Fig. 4). This has raised the possibility of
bisubstrate-type inhibitors or intermediate-analogue inhibi-
tors which emulate the structural features of both substrates
(i.e. of compounds 1 and 2). Using 20 compounds of this
structural type, we performed preliminary inhibition tests with
BaLS. The three compounds with the highest inhibitory
potential (compounds TS23, JC33 and JC72) were selected for
detailed kinetic analysis.
3.5. Kinetic assay of lumazine synthase inhibitors
The LS inhibitors JC33, JC72 and TS23 were tested as
inhibitors of recombinant BaLS using a kinetic assay (Fig. 5).
The inhibition constants and inhibition mechanisms for these
inhibitors are listed in Table 3.
The data show that all three compounds are potent inhi-
bitors of the enzyme, with Ki values in the low nanomolar
range. The most potent inhibitor is compound JC33
(Ki =2 3n M), which contains a phosphobutyl moiety as a side
chain. The insertion of a carbonyl group into this side chain
leads to compound TS23 with an oxopentylphosphate side
chain and increases the Ki value sevenfold (to 140 nM)i n
comparison to JC33. A pentylphosphonate moiety in
compound JC72 increases the Ki value by approximately 20-
fold (to 430 nM) in comparison to JC33.
Previously, we reported that the alkylphosphate moiety
plays an important role in the binding of certain inhibitors to
the active site of MtLS (Cushman et al., 2004; Morgunova et
al., 2005). The ribityl side chain of the tested inhibitors seemed
to be equally important, at least with respect to inhibitors
binding to MtLS. The fact that inhibitor JC33, which is devoid
of a ribityl side chain, has a high inhibition potency for BaLS,
with a Ki of 23 nM, makes it an attractive lead compound for
the discovery of new anti-infective agents against anthrax.
3.6. Isothermal titration calorimetry
The thermodynamics of inhibitor binding by BaLS were
studied by isothermal titration calorimetry (ITC). The
apparent association constant, stoichiometry and binding
enthalpy were derived from ﬁtting of the binding isotherms.
Fig. 6 shows typical calorimetric titration curves of BaLS in
50 mM phosphate buffer at pH 7.0 and T = 303 K. Thermo-
dynamic characteristics such as the entropy and free energy
of binding were deduced from the Gibbs–Helmholtz equation
[G =  RTln(Ka)=H   TS; see also x2]. All three
binding reactions were found to be exothermic, with favour-
able negative changes of the binding enthalpy H. Interest-
ingly, all three binding reactions are characterized by positive
changes in TS. Thus, the small changes in enthalpy were
compensated by corresponding favourable positive changes in
entropy. The resulting free-energy values are similar for all
three complexes. For comparison, the thermodynamic char-
acteristics of complexes of JC33 with MtLS and C. albicans LS
(CaLS) are presented in the two right-hand columns of Table
4. The dissociation constants of both complexes with penta-
meric enzymes are almost tenfold lower than for the icosa-
hedral BaLS. The changes in free binding energy are higher in
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Figure 5
Kinetics plots for the inhibition of B. anthracis LS by the following
inhibitors: JC33 (a), TS23 (b) and JC72 (c). The inhibitor concentrations
were 0 mM (squares), 5 mM (diamonds), 15 mM (circles) or 45 mM
(triangles). The inset in (a) shows an extended view of the same plot in
the region OD408 = 0 for inhibitor concentrations of 5, 15 and 45 mM.the complexes of pentameric enzymes compared with the
BaLS–JC33 complex. The entropy changes for the binding of
all three inhibitors by BaLS as well as the entropy change of
the binding of JC33 by CaLS were found to be positive,
whereas MtLS binds JC33 with an unfavourable negative
change in entropy. The overlaid structures of the active sites of
BaLS with CaLS and MtLS and sequence alignment showed
that the position of the residue located near Arg126 in the
active site is occupied by Gly132 in BaLS and by His148 in
CaLS; however, this position is occupied by a negatively
charged glutamate residue in MtLS. The binding of the inhi-
bitors is accompanied by a dislocation of water molecules
present in the active site of the unliganded enzyme. Thus, it
seems unrealistic to attempt an interpretation of the positive
entropy changes in molecular terms with respect to speciﬁc
features of the inhibitors.
3.7. Structure-based modelling of the inhibitors in the active
site of BaLS
No major conformational changes have been found to
accompany the binding of inhibitors to the known LS ortho-
logues, with the exception of the aromatic amino-acid residue
(Phe or Tyr) in position 21 (Ladenstein et al., 1988; Meining et
al., 2000; Gerhardt et al., 2002; Zhang et al., 2003; Klinke et al.,
2005; Morgunova et al., 2005, 2006). The respective benzenoid
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Table 3
Inhibition constants for B. anthracis lumazine synthase.
Experiments were conducted with recombinant BaLS. The assays were performed with the concentration of compound 2 (see Fig. 1) held constant, while the
concentration of compound 1 was varied. Reaction mixtures contained 100 mM Tris–HCl pH 7.0, 100 mM NaCl and 5 mM DTT. For the competitive mechanism it
is assumed that the inhibitor binds at the substrate (compound 1) binding site and inactivates the enzyme completely. This model is described by the following
chemical equations: E + S $ ES (substrate binding at enzyme), Ks is the dissociation constant for this equilibrium; ES ! E + P (conversion of the enzyme–
substrate complex into enzyme and product), kcat is the rate constant for this process; E + I $ EI (binding of inhibitor at the binding site for the substrate, i.e.
compound 1), Ki is the inhibitor-dissociation constant for this equilibrium. For the partial mechanism it is assumed that the inhibitor binds at the binding site for
compound 1 and inactivates the enzyme completely. In parallel it can bind at the enzyme away from the binding site for compound 1. In this case it can only
partially inactivate the enzyme. This model is described by the following chemical equations: E + S $ ES (substrate binding by enzyme), Ks is the dissociation
constant for this equilibrium; ES ! E + P (conversion of the enzyme–substrate complex into enzyme and product), kcat is the rate constant for this process; E + I
$ EI (binding of inhibitor at the binding site for compound 1), Ki is the inhibitor-dissociation constant for this equilibrium; ES + I $ ESI (binding of the inhibitor
away from the binding site for compound 1), Kis is the inhibitor-dissociation constant for this equilibrium; ESI ! E + I + P [conversion of the triple complex
(enzyme–substrate–inhibitor) into enzyme, inhibitor and product], k0
cat is the rate constant for this process. A numerical solution to the problem of minimizing a
least-squares function over a space of reaction parameters was found using the Levenberg–Marquardt algorithm.
Compound Mechanism Ks (mM) kcat (min
 1) Ki (mM) Kis (mM) k0
cat (min
 1)
JC33 Competitive 8.0   0.5 0.60   0.01 0.023   0.006
JC72 Partial 8.5   0.5 0.60   0.01 0.43   0.06 9.5   3.5 0.28   0.09
TS23 Partial 8.3   0.4 0.60   0.01 0.14   0.03 0.85   0.2 0.08   0.01
Figure 6
Raw calorimetric data (top) and derived binding isotherms (bottom) for the titration of lumazine synthase from B. anthracis with JC33 (a), JC72 (b) and
TS23 (c). The ﬁlled squares in the binding isotherms represent the experimental values of the heat changes at each injection; the continuous lines
represent the results of the data ﬁtting to the chosen binding model. 1 cal = 4.186 J.ring is oriented parallel to the plane of the aromatic group of
the inhibitor, whereas the same group in the apo structures
assumed different conformations in different subunits of the
same molecule (Persson et al., 1999; Braden et al., 2000; Zhang
et al., 2001; Morgunova et al., 2007; present structure). By
using the structural information from a substantial number of
LS structures with phosph(on)oalkyl ligands, we have initiated
docking studies of inhibitors in the active site of BaLS and we
present here the hypothetical binding modes for complexes of
BaLS with the three inhibitors described above. The docking
calculations revealed different possible positions and orien-
tations of binding of all three inhibitors (Fig. 7). The active site
of LSs is rather large and can be occupied by inhibitors which
are more bulky than the derivatives of the substrate, com-
pound 1 (Fig. 1), presented in this work (for example, luma-
zine or purine derivatives containing both ribityl and aliphatic
side chains). The hypothetical binding modes of all three
inhibitors are very similar to that found in the structure of the
MtLS–JC33 complex with respect to the different amino acids
in the active site. The aromatic rings of the inhibitors are
found in close proximity to the benzene ring of Phe21 at a
distance of 4.3–4.6 A ˚ and the phosphate/phosphonate moieties
are exposed to the locations of the side chains of Arg126 and
Thr85. Slightly different conformations of the inhibitors were
observed with different lengths of their aliphatic chains, which
can be explained by the packing strain exerted on those chains
by the available space. Molecular-dynamics calculations
followed by energy minimization of the favourable models
performed with CNS moved the side chain of Phe21 into a
conformation that is parallel to the position of the aromatic
ring of the inhibitors, as expected. Thus, the pyrimidine rings
of all three inhibitors form stacking aromatic interactions with
the benzene ring of the phenylalanine residue, although the
rings of the inhibitors are slightly shifted with respect to each
other. The phosphonate moiety of JC72 occupies the same
position as the phosphate moiety of JC33, although the pyri-
midine ring of JC72 is slightly shifted relative to the pyrimi-
dine ring of JC33. A possible explanation is the presence of an
additional C atom in the aliphatic chain of JC72 in comparison
with JC33. The compound TS23 has the same-length aliphatic
chain as JC72 with an additional carbonyl O atom attached to
the aliphatic chain in the position next to the pyrimidine ring.
The binding mode of this inhibitor shows a different packing
of the aliphatic chain in the active-site space, with the phos-
phate moiety shifted slightly closer to the side chain of
Arg126. This phosphate moiety is involved in ion-pair bonding
with the guanidyl group of the side chain of Arg126 and in
addition interacts with the side chain of Thr85 (Fig. 7). Thus,
the differences found in the thermodynamic constants of
binding of the JC72 and TS23 inhibitors compared with JC33,
as well as the lower binding constant, can be
explained by increasing difﬁculty in packing
the longer aliphatic chain of those inhibitors
into the active-site space. This conclusion
agrees with our previous results of the
investigation of the optimum length of the
aliphatic chain of purinetrione inhibitors,
which showed that the most favourable
binding characteristics are shown by the
compounds with an aliphatic chain
consisting of 4–5 C atoms (Morgunova et al.,
2006, 2007).
We gratefully acknowledge the access to
synchrotron-radiation facilities at the ESRF
outstation. We thank Dr Luca Jovine for the
help with PHENIX for the reﬁnement of
90 protein subunits in the asymmetric unit.
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Table 4
Thermodynamic parameters of binding of different inhibitors to B. anthracis lumazine synthase.
1 kcal = 4.186 kJ.
BaLS–TS23 BaLS–JC72 BaLS–JC33
MtLS–JC33
(Morgunova et al., 2006)
CaLS–JC33
(Morgunova et al., 2007)
No. of sites n 0.97   0.06 0.98   0.12 0.98   0.04 0.98   0.04 1.15   0.03
Dissociation constant Kd (mM) 2.02   0.03 3.94   0.01 1.75   0.04 0.72   0.02 0.15   0.04
Binding enthalpy H (kcal mol
 1)  3.70   0.27  5.29   0.8  7.50   0.07  10.52   0.11  6.98   0.24
TS† (kcal mol
 1) 4.19   0.27 2.20   0.79 0.47   0.07  2.00   0.12 2.44   0.25
Free energy of binding G† (kcal mol
 1)  7.89   0.01  7.49   0.01  7.98   0.02  8.52   0.05  9.38   0.01
† The entropy of the binding reactions (S) and the free-energy change (G) are obtained from the relation G =  RTln(Ka)=H   TS; the estimated errors of TS and G are
obtained from the relations  G = ðRT=KaÞ Ka and T S ={ [ ( dS/dG) G]
2 +[ ( dS/dH) H]
2}
1/2 =[ (  G)
2 +(  H)
2]
1/2, respectively (Taylor, 1997).
Figure 7
Stereo diagram of the active site of lumazine synthase from B. anthracis with docked models of
JC33 (shown in cyan), JC72 (shown in magenta) and TS23 (shown in orange); residues of the
adjacent symmetry-equivalent subunit are labelled with primes.This work was supported by the Swedish Research Council
(Vetenskapsra ˚det; project 621-2007-6113) and the Hans
Fischer Gesellschaft. The synthesis of the three lumazine
synthase inhibitors was made possible by NIH grant
GM51469.
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